Cargando…
Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors
Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303312/ https://www.ncbi.nlm.nih.gov/pubmed/35073610 http://dx.doi.org/10.1002/cmdc.202100755 |
_version_ | 1784751833214877696 |
---|---|
author | Schäker‐Hübner, Linda Haschemi, Reza Büch, Thomas Kraft, Fabian B. Brumme, Birke Schöler, Andrea Jenke, Robert Meiler, Jens Aigner, Achim Bendas, Gerd Hansen, Finn K. |
author_facet | Schäker‐Hübner, Linda Haschemi, Reza Büch, Thomas Kraft, Fabian B. Brumme, Birke Schöler, Andrea Jenke, Robert Meiler, Jens Aigner, Achim Bendas, Gerd Hansen, Finn K. |
author_sort | Schäker‐Hübner, Linda |
collection | PubMed |
description | Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI‐994) and evaluated their solubility, lipophilicity (log D(7.4)) and inhibition of selected HDAC isoforms. Subsequently, we selected the most promising “capless” HDACi and transferred its ZBG to our previously published scaffold featuring a peptoid‐based cap group. The resulting hit compound 10 c (LSH‐A54) showed favorable physicochemical properties and is a potent, selective HDAC1/2 inhibitor. The following evaluation of its slow binding properties revealed that LSH‐A54 binds tightly to HDAC1 in an induced‐fit mechanism. The potent HDAC1/2 inhibitory properties were reflected by attenuated cell migration in a modified wound healing assay and reduced cell viability in a clonogenic survival assay in selected breast cancer cell lines. |
format | Online Article Text |
id | pubmed-9303312 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93033122022-07-22 Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors Schäker‐Hübner, Linda Haschemi, Reza Büch, Thomas Kraft, Fabian B. Brumme, Birke Schöler, Andrea Jenke, Robert Meiler, Jens Aigner, Achim Bendas, Gerd Hansen, Finn K. ChemMedChem Research Articles Herein we report the structure‐activity and structure‐physicochemical property relationships of a series of class I selective ortho‐aminoanilides targeting the “foot‐pocket” in HDAC1&2. To balance the structural benefits and the physicochemical disadvantages of these substances, we started with a set of HDACi related to tacedinaline (CI‐994) and evaluated their solubility, lipophilicity (log D(7.4)) and inhibition of selected HDAC isoforms. Subsequently, we selected the most promising “capless” HDACi and transferred its ZBG to our previously published scaffold featuring a peptoid‐based cap group. The resulting hit compound 10 c (LSH‐A54) showed favorable physicochemical properties and is a potent, selective HDAC1/2 inhibitor. The following evaluation of its slow binding properties revealed that LSH‐A54 binds tightly to HDAC1 in an induced‐fit mechanism. The potent HDAC1/2 inhibitory properties were reflected by attenuated cell migration in a modified wound healing assay and reduced cell viability in a clonogenic survival assay in selected breast cancer cell lines. John Wiley and Sons Inc. 2022-02-18 2022-05-04 /pmc/articles/PMC9303312/ /pubmed/35073610 http://dx.doi.org/10.1002/cmdc.202100755 Text en © 2022 The Authors. ChemMedChem published by Wiley-VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Schäker‐Hübner, Linda Haschemi, Reza Büch, Thomas Kraft, Fabian B. Brumme, Birke Schöler, Andrea Jenke, Robert Meiler, Jens Aigner, Achim Bendas, Gerd Hansen, Finn K. Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors |
title | Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors |
title_full | Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors |
title_fullStr | Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors |
title_full_unstemmed | Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors |
title_short | Balancing Histone Deacetylase (HDAC) Inhibition and Drug‐likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors |
title_sort | balancing histone deacetylase (hdac) inhibition and drug‐likeness: biological and physicochemical evaluation of class i selective hdac inhibitors |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303312/ https://www.ncbi.nlm.nih.gov/pubmed/35073610 http://dx.doi.org/10.1002/cmdc.202100755 |
work_keys_str_mv | AT schakerhubnerlinda balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT haschemireza balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT buchthomas balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT kraftfabianb balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT brummebirke balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT scholerandrea balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT jenkerobert balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT meilerjens balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT aignerachim balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT bendasgerd balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors AT hansenfinnk balancinghistonedeacetylasehdacinhibitionanddruglikenessbiologicalandphysicochemicalevaluationofclassiselectivehdacinhibitors |